To date, the Food and Drug Administration (FDA) has approved Guardant360® CDx (Guardant Health, Redwood City, CA, USA, 2020), the first liquid biopsy NGS ctDNA assay for therapeutic decisions on the use of osimertinib, a second-generation tyrosine kinase inhibitor, in NSCLC patients with EGFR mutations [67]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.